| abstract |
The present invention relates to a pharmaceutical liposome composition comprising 2-{[5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy] Phenyl}-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy}-3-(2-{[2-(2-methoxyphenyl) pyrimidin-4-yl]methoxy}phenyl)propionic acid (referred to as 'Compound A') or a pharmaceutically acceptable salt thereof. More specifically, the present invention relates to liposome carriers, organic concentrate compositions comprising Compound A, and pharmaceutical compositions comprising liposomes and Compound A for parenteral administration. Furthermore, the present invention also relates to the use of the composition for the treatment of cancer. 'Compound A' as used herein includes all enantiomers, diastereomers and atropisomers thereof or mixtures thereof and optionally pharmaceutically acceptable salts thereof. |